StockData
Entrada Therapeutics, Inc. logo

Entrada Therapeutics, Inc. (TRDA) stock

TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$5.00−0.09 (-1.77%)

Close on Nov 16, 2026Market cap $194.68MP/E –Yield –

Entrada Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Entrada Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$134.67M. For fiscal 2025 it was -$128.51M. The highest annual figure on record is $139.80M in fiscal 2023.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$128.51M–
FY2024Dec 31, 2024-$41.56M-129.7%
FY2023Dec 31, 2023$139.80M–
FY2022Dec 31, 2022-$93.79M–
FY2021Dec 31, 2021-$50.86M–
FY2020Dec 31, 2020-$25.57M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$32.46M–
Q1 FY2026Mar 31, 2026-$41.70M–
Q4 FY2025Dec 31, 2025-$32.20M–
Q3 FY2025Sep 30, 2025-$28.31M–
Q2 FY2025Jun 30, 2025-$29.49M-174.0%
Q1 FY2025Mar 31, 2025-$38.51M–
Q4 FY2024Dec 31, 2024-$31.61M–
Q3 FY2024Sep 30, 2024-$24.27M–
Q2 FY2024Jun 30, 2024$39.83M–
Q1 FY2024Mar 31, 2024-$25.52M-112.5%
Q4 FY2023Dec 31, 2023-$4.01M–
Q3 FY2023Sep 30, 2023-$24.49M–
Q2 FY2023Jun 30, 2023-$35.09M–
Q1 FY2023Mar 31, 2023$203.40M–
Q4 FY2022Dec 31, 2022-$27.30M–
Q3 FY2022Sep 30, 2022-$27.48M–
Q2 FY2022Jun 30, 2022-$18.01M–
Q1 FY2022Mar 31, 2022-$20.99M–
Q4 FY2021Dec 31, 2021-$20.54M–
Q3 FY2021Sep 30, 2021-$14.08M–
Q2 FY2021Jun 30, 2021-$7.91M–
Q1 FY2021Mar 31, 2021-$8.34M–
Q4 FY2020Dec 31, 2020-$6.62M–

More Entrada Therapeutics figures

See a number that looks wrong?